Pfizer Inc. (NYSE:PFE) Shares Purchased by Fulton Bank N.A.

Fulton Bank N.A. boosted its stake in Pfizer Inc. (NYSE:PFE) by 7.9% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 125,282 shares of the biopharmaceutical company’s stock after acquiring an additional 9,188 shares during the period. Fulton Bank N.A.’s holdings in Pfizer were worth $3,626,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the stock. EHP Funds Inc. boosted its holdings in Pfizer by 10.0% in the 4th quarter. EHP Funds Inc. now owns 11,000 shares of the biopharmaceutical company’s stock valued at $317,000 after purchasing an additional 1,000 shares in the last quarter. Elo Mutual Pension Insurance Co boosted its stake in shares of Pfizer by 4.3% during the 4th quarter. Elo Mutual Pension Insurance Co now owns 492,928 shares of the biopharmaceutical company’s stock worth $14,191,000 after acquiring an additional 20,438 shares in the last quarter. XML Financial LLC boosted its stake in shares of Pfizer by 2.4% during the 4th quarter. XML Financial LLC now owns 191,949 shares of the biopharmaceutical company’s stock worth $5,526,000 after acquiring an additional 4,480 shares in the last quarter. Allen Wealth Management LLC purchased a new stake in shares of Pfizer during the 4th quarter worth approximately $2,224,000. Finally, Humankind Investments LLC lifted its stake in Pfizer by 22.0% in the 4th quarter. Humankind Investments LLC now owns 74,285 shares of the biopharmaceutical company’s stock valued at $2,139,000 after buying an additional 13,406 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Trading Up 2.2 %

Shares of PFE stock traded up $0.62 on Monday, reaching $29.20. 51,228,953 shares of the stock were exchanged, compared to its average volume of 37,456,285. The stock has a market cap of $165.46 billion, a P/E ratio of -486.83, a price-to-earnings-growth ratio of 1.23 and a beta of 0.67. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. The firm has a 50 day moving average of $29.17 and a two-hundred day moving average of $28.32. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $33.92.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The firm had revenue of $13.28 billion during the quarter, compared to analysts’ expectations of $12.96 billion. During the same period in the prior year, the company earned $0.67 EPS. The firm’s revenue was up 2.1% on a year-over-year basis. On average, research analysts anticipate that Pfizer Inc. will post 2.66 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on PFE. Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Wells Fargo & Company upped their target price on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. StockNews.com downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Tuesday, October 1st. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and boosted their price target for the company from $28.00 to $34.00 in a report on Wednesday, August 7th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a report on Thursday. Nine research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $34.54.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.